zantac 150 mg filmtabletta
eu pharma kft. - ranitidin -
mitoxantrone accord 2 mg/ml koncentrátum oldatos injekcióhoz vagy infúzióhoz
accord healthcare polska sp. z o.o. - mitoxantrone -
ranitidine accord 150 mg filmtabletta
accord healthcare polska sp. z o.o. - ranitidin -
ranitidine accord 300 mg filmtabletta
accord healthcare polska sp. z o.o. - ranitidin -
tagrisso
astrazeneca ab - osimertinib mesilate - karcinóma, nem kissejtes tüdő - egyéb daganatellenes szerek, a protein kináz inhibitorok - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.